IL18 and inflammatory bowel disease: Neutralization of IL-18 with IL-18BP or anti-IL-18 antibodies demonstrated efficacy in dextran sodium sulfate (DSS)- or trinitrobenzoic sulphonic acid (TNSB)- induced models of IBD, and reduces intestinal IFNγ and TNFα, further proving the concept of IL-18 as a pivotal mediator in experimental colitis (60, 62, 63).